Allegro’s Luminate Achieves Primary Endpoint in DME Trial (OIS@AAO 2016)

Opthea Eye Phase IIB Trial in 2017 (OIS@AAO 2016)Подробнее

Vitrectomy for Diabetic Macular Edema (DME) and Subfoveal Hard Exudat PlaquesПодробнее

Straught implants where shallow mental foramenПодробнее

Allegro Ophthalmics: First-in-Class Anti-Integrin Agent (OIS@ASRS 2016)Подробнее

Allegro Ophthalmics Reports Phase II Data for LuminateПодробнее

Allegro Plans for Phase III of LuminateПодробнее

Clinical Trial: RO7200220 for Diabetic Macular Edema (NCT05151744)Подробнее

Allegro Ophthalmics - OIS@AAO 2015Подробнее

Dr. Wright on PFS as an Endpoint in Ovarian Cancer TrialsПодробнее

Alimera Sciences: Addressing DME with Persistent Microdose Therapy (OIS@ASRS 2016)Подробнее

Allegro Ophthalmics - Innovation Showcase at Ophthalmology Innovation Summit @ AAO 2019Подробнее

Clinical trials for diabetic retinopathy. Introduction to Protocol TПодробнее

Allgenesis, A New Era in Diabetic Macular Edema: Insights from AG-73305Подробнее

Thomas Ciulla: Real-World Outcomes for DME PatientsПодробнее

OCT Connect Case PresentationsПодробнее

AAO DME in the Real WorldПодробнее

Diabetic Macular Edema DMEПодробнее